Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Optimal benefits for hematopoietic stem cell transplantation: a consensus opinion.

Maziarz RT, Farnia S, Martin P, Komanduri KV.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1671-6. doi: 10.1016/j.bbmt.2014.07.007. Epub 2014 Jul 12.

2.

'The Mexican approach' to conduct NST.

Ruiz-Argüelles GJ.

Eur J Haematol. 2001 Nov-Dec;67(5-6):335. No abstract available.

PMID:
11872085
3.

Umbilical cord blood banking: implications for perinatal care providers.

Armson BA; Maternal/Fetal Medicine Committee, Society of Obstetricians and Gynaecologists of Canada.

J Obstet Gynaecol Can. 2005 Mar;27(3):263-90. English, French. Erratum in: J Obstet Gynaecol Can. 2005 Jul;27(7):673.

PMID:
15943003
4.

Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer.

LeMaistre CF, Farnia SH.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1367-72. doi: 10.1016/j.bbmt.2015.04.014. Epub 2015 Apr 16. Review.

5.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W; International Myeloma Working Group.

J Clin Oncol. 2010 Oct 10;28(29):4521-30. doi: 10.1200/JCO.2010.29.7929. Epub 2010 Aug 9.

PMID:
20697091
7.

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64. doi: 10.1016/j.bbmt.2011.12.581. Epub 2011 Dec 23.

8.

Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.

Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.

9.

[Allogeneic hematopoietic stem cell transplantations].

Michallet M.

Transfus Clin Biol. 2011 Apr;18(2):235-45. doi: 10.1016/j.tracli.2011.02.021. Epub 2011 Apr 3. Review. French.

PMID:
21466967
10.

Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

Mattsson J, Uzunel M, Remberger M, Tammik L, Omazic B, Levitsky V, Zou JZ, Hentschke P, Ringdén O.

Clin Exp Immunol. 2001 Jan;123(1):162-9.

11.

Hematopoietic stem cell transplantation procedures.

Saccardi R, Gualandi F.

Autoimmunity. 2008 Dec;41(8):570-6. doi: 10.1080/08916930802197776. Review.

PMID:
18958744
12.

Financial burden in recipients of allogeneic hematopoietic cell transplantation.

Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, Noel P, Fauble V, Sproat L, Tilburt J, Leis JF, Mikhael J.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81. doi: 10.1016/j.bbmt.2014.05.011. Epub 2014 May 24.

13.

Demystyfication versus trivialization of stem cell transplantation.

Borbolla JR, González-Avante M, Siller AJ.

Haematologica. 2001 Mar;86(3):E06-E07. No abstract available.

PMID:
11255293
14.

Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.

Dean R, Masci P, Pohlman B, Andresen S, Serafino S, Sobecks R, Kuczkowski E, Curtis J, Maciejewski J, Rybicki L, Kalaycio M, Hsi E, Theil K, Bolwell BJ.

Bone Marrow Transplant. 2005 Dec;36(12):1049-52.

PMID:
16247431
15.

Allogeneic hematopoietic stem-cell transplantation for myeloma: it's time for the appropriate studies.

Gratwohl A.

J Clin Oncol. 2011 Jun 1;29(16):e483; author reply e484. doi: 10.1200/JCO.2010.34.4481. Epub 2011 Apr 4. No abstract available.

PMID:
21464404
16.

Economics of hematopoietic cell transplantation.

Khera N, Zeliadt SB, Lee SJ.

Blood. 2012 Aug 23;120(8):1545-51. doi: 10.1182/blood-2012-05-426783. Epub 2012 Jun 13.

17.

Stem cell transplantation for multiple myeloma: current status and future directions.

Caldera H, Giralt S.

Curr Hematol Rep. 2004 Jul;3(4):249-56. Review.

PMID:
15217554
18.

Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.

Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC.

Am J Hematol. 2001 Apr;66(4):241-4.

19.

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.

Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R.

Rev Clin Exp Hematol. 2001 Jun;5(2):135-46. Review.

PMID:
11486652
20.

Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.

Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M.

Hematol Oncol Stem Cell Ther. 2011;4(1):1-9. Review.

Supplemental Content

Support Center